Vienna, Austria

Eva Prieschl

This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Marinomed Biotechnologie Gmbh. Active years: 2018.

USPTO Granted Patents = 1 

% Patents Active = 100.0


Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Eva Prieschl: Innovator in Pharmaceutical Preparations

Introduction

Eva Prieschl is a notable inventor based in Vienna, Austria. She has made significant contributions to the field of pharmaceuticals, particularly in the treatment of diseases mediated by activated granulocytes. Her innovative work has led to the development of a unique pharmaceutical preparation that addresses critical health issues.

Latest Patents

Eva Prieschl holds a patent for the use of escin in the manufacture of a pharmaceutical preparation. This invention is particularly aimed at treating diseases caused by activated granulocytes, such as type I or type III allergies and septic shock. Her patent represents a significant advancement in therapeutic options for these conditions.

Career Highlights

Eva Prieschl is associated with Marinomed Biotechnologie GmbH, a company known for its cutting-edge research in biotechnology. Her role at the company has allowed her to focus on innovative solutions in the pharmaceutical industry. With her expertise, she has contributed to the development of effective treatments that can improve patient outcomes.

Collaborations

Eva collaborates with Andreas Grassauer, who is also a key figure in her research endeavors. Their partnership exemplifies the importance of teamwork in driving innovation within the biotechnology sector.

Conclusion

Eva Prieschl's contributions to pharmaceutical preparations highlight her role as a leading inventor in the field. Her work not only advances medical science but also offers hope for patients suffering from serious health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…